MECHANISM OF ACTION:
Pimozid is a member of the Diphenyl-Butyl-Piperidine group, structurally similar to haloperidol. It is thought to block CNS dopaminergic receptors. It has no effect on noradernaline receptors.
INDICATIONS:
Pimozid is indicated for acute and chronic schizophrenia, mania and hypomania, as an adjunct to the short term management of moderate to severe psychomotor agitation and excitement.